Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors.

Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA.

Arthritis Rheumatol. 2019 Aug 5. doi: 10.1002/art.41073. [Epub ahead of print]

PMID:
31379071
2.

Long-Term Safety and Efficacy of Gene-Pulmonary Macrophage Transplantation Therapy of PAP in Csf2ra-/- Mice.

Arumugam P, Suzuki T, Shima K, McCarthy C, Sallese A, Wessendarp M, Ma Y, Meyer J, Black D, Chalk C, Carey B, Lachmann N, Moritz T, Trapnell BC.

Mol Ther. 2019 Jul 2. pii: S1525-0016(19)30305-3. doi: 10.1016/j.ymthe.2019.06.010. [Epub ahead of print]

PMID:
31326401
3.

Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation: Mechanistic Implications for Desquamative Interstitial Pneumonitis.

Suzuki T, McCarthy C, Carey B, Borchers M, Beck D, Wikenheiser-Brokamp KA, Black D, Chalk C, Trapnell BC.

Am J Respir Cell Mol Biol. 2019 Jul 16. doi: 10.1165/rcmb.2018-0294OC. [Epub ahead of print]

PMID:
31310562
4.

Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis.

Hetzel M, Lopez-Rodriguez E, Mucci A, Nguyen AHH, Suzuki T, Shima K, Buchegger T, Dettmer S, Rodt T, Bankstahl JP, Malik P, Knudsen L, Schambach A, Hansen G, Trapnell BC, Lachmann N, Moritz T.

Haematologica. 2019 Jul 9. pii: haematol.2018.214866. doi: 10.3324/haematol.2018.214866. [Epub ahead of print]

5.

Complete Tracheal Ring Deformity: A Translational Genomics Approach to Pathogenesis.

Sinner DI, Carey B, Zgherea D, Kaufman KM, Leesman L, Wood RE, Rutter MJ, de Alarcon A, Elluru RG, Harley JB, Whitsett JA, Trapnell BC.

Am J Respir Crit Care Med. 2019 Jun 19. doi: 10.1164/rccm.201809-1626OC. [Epub ahead of print]

PMID:
31215789
6.

The Alveolar Lipidome in Pulmonary Alveolar Proteinosis: A New Focus for Therapeutic Development?

Trapnell BC, McCarthy C.

Am J Respir Crit Care Med. 2019 Jun 4. doi: 10.1164/rccm.201905-1009ED. [Epub ahead of print] No abstract available.

PMID:
31162934
7.

Pulmonary alveolar proteinosis.

Trapnell BC, Nakata K, Bonella F, Campo I, Griese M, Hamilton J, Wang T, Morgan C, Cottin V, McCarthy C.

Nat Rev Dis Primers. 2019 Mar 7;5(1):16. doi: 10.1038/s41572-019-0066-3. Review.

PMID:
30846703
8.

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.

Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX; NIH Rare Lung Disease Consortium.

Eur Respir J. 2019 Apr 4;53(4). pii: 1802066. doi: 10.1183/13993003.02066-2018. Print 2019 Apr.

PMID:
30846465
9.

Automated Parenchymal Pattern Analysis of Treatment Responses in Pulmonary Alveolar Proteinosis.

McCarthy C, Bartholmai BJ, Woods JC, McCormack FX, Trapnell BC.

Am J Respir Crit Care Med. 2019 May 1;199(9):1151-1152. doi: 10.1164/rccm.201810-1918IM. No abstract available.

PMID:
30822107
10.

Blood Testing for Differential Diagnosis of Pulmonary Alveolar Proteinosis Syndrome.

McCarthy C, Carey B, Trapnell BC.

Chest. 2019 Feb;155(2):450-452. doi: 10.1016/j.chest.2018.11.002. No abstract available.

PMID:
30732696
11.

Blood testing in the diagnosis of pulmonary alveolar proteinosis.

McCarthy C, Carey B, Trapnell BC.

Lancet Respir Med. 2018 Nov;6(11):e54. doi: 10.1016/S2213-2600(18)30372-2. No abstract available.

PMID:
30484430
12.

Statin as a novel pharmacotherapy of pulmonary alveolar proteinosis.

McCarthy C, Lee E, Bridges JP, Sallese A, Suzuki T, Woods JC, Bartholmai BJ, Wang T, Chalk C, Carey BC, Arumugam P, Shima K, Tarling EJ, Trapnell BC.

Nat Commun. 2018 Aug 7;9(1):3127. doi: 10.1038/s41467-018-05491-z.

13.

Prevalence and healthcare burden of pulmonary alveolar proteinosis.

McCarthy C, Avetisyan R, Carey BC, Chalk C, Trapnell BC.

Orphanet J Rare Dis. 2018 Jul 31;13(1):129. doi: 10.1186/s13023-018-0846-y.

14.

Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis.

McCarthy C, Brewington JJ, Harkness B, Clancy JP, Trapnell BC.

Eur Respir J. 2018 Jun 7;51(6). pii: 1702457. doi: 10.1183/13993003.02457-2017. Print 2018 Jun. No abstract available.

PMID:
29563174
15.

IFN-β Improves Sepsis-related Alveolar Macrophage Dysfunction and Postseptic Acute Respiratory Distress Syndrome-related Mortality.

Hiruma T, Tsuyuzaki H, Uchida K, Trapnell BC, Yamamura Y, Kusakabe Y, Totsu T, Suzuki T, Morita S, Doi K, Noiri E, Nakamura K, Nakajima S, Yahagi N, Morimura N, Chang K, Yamada Y.

Am J Respir Cell Mol Biol. 2018 Jul;59(1):45-55. doi: 10.1165/rcmb.2017-0261OC.

PMID:
29365277
16.

Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.

Wright SS, Trauernicht A, Bonkowski E, McCall CA, Maier EA, Bezold R, Lake K, Chalk C, Trapnell BC, Kim MO, Kugathasan S, Denson LA.

J Pediatr Gastroenterol Nutr. 2018 May;66(5):767-772. doi: 10.1097/MPG.0000000000001851.

17.

Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.

McCarthy C, Lara Gallego B, Trapnell BC, McCormack FX.

Adv Exp Med Biol. 2017;1031:419-442. doi: 10.1007/978-3-319-67144-4_24. Review.

PMID:
29214586
18.

Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease.

Aoki A, Sakagami T, Yoshizawa K, Shima K, Toyama M, Tanabe Y, Moro H, Aoki N, Watanabe S, Koya T, Hasegawa T, Morimoto K, Kurashima A, Hoshino Y, Trapnell BC, Kikuchi T.

Clin Infect Dis. 2018 Apr 3;66(8):1239-1245. doi: 10.1093/cid/cix996.

PMID:
29126235
19.

Does Granulocyte-Macrophage Colony-Stimulating Factor Coordinate a Hepatopulmonary Axis of Lipid Metabolism?

Trapnell BC, Bridges J.

Am J Respir Cell Mol Biol. 2017 Oct;57(4):383-385. doi: 10.1165/rcmb.2017-0191ED. No abstract available.

PMID:
28960104
20.

Targeting cholesterol homeostasis in lung diseases.

Sallese A, Suzuki T, McCarthy C, Bridges J, Filuta A, Arumugam P, Shima K, Ma Y, Wessendarp M, Black D, Chalk C, Carey B, Trapnell BC.

Sci Rep. 2017 Aug 31;7(1):10211. doi: 10.1038/s41598-017-10879-w.

21.

Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency.

Hetzel M, Suzuki T, Hashtchin AR, Arumugam P, Carey B, Schwabbauer M, Kuhn A, Meyer J, Schambach A, Van Der Loo J, Moritz T, Trapnell BC, Lachmann N.

Hum Gene Ther Methods. 2017 Dec;28(6):318-329. doi: 10.1089/hgtb.2017.092. Epub 2017 Aug 30.

22.

An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases.

Kristof AS, Petrof BJ, Hamid Q, Kolb M, Landry JS, MacKenzie A, McCormack FX, Murawski IJ, Moss J, Rauch F, Rosas IO, Shapiro AJ, Smith BM, Thomas DY, Trapnell BC, Young LR, Zariwala MA; ATS Assembly on Respiratory Cell and Molecular Biology.

Ann Am Thorac Soc. 2017 Aug;14(8):1239-1247. doi: 10.1513/AnnalsATS.201705-406WS.

23.

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study.

Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M, Mondal K, Liu C, Griffiths A, Noe JD, Crandall WV, Snapper S, Rabizadeh S, Rosh JR, Shapiro JM, Guthery S, Mack DR, Kellermayer R, Kappelman MD, Steiner S, Moulton DE, Keljo D, Cohen S, Oliva-Hemker M, Heyman MB, Otley AR, Baker SS, Evans JS, Kirschner BS, Patel AS, Ziring D, Trapnell BC, Sylvester FA, Stephens MC, Baldassano RN, Markowitz JF, Cho J, Xavier RJ, Huttenhower C, Aronow BJ, Gibson G, Hyams JS, Dubinsky MC.

Lancet. 2017 Apr 29;389(10080):1710-1718. doi: 10.1016/S0140-6736(17)30317-3. Epub 2017 Mar 2.

24.
25.

Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters J, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Orphanet J Rare Dis. 2016 Aug 31;11(1):115. doi: 10.1186/s13023-016-0497-9.

26.

Pulmonary Alveolar Proteinosis Syndrome.

Suzuki T, Trapnell BC.

Clin Chest Med. 2016 Sep;37(3):431-40. doi: 10.1016/j.ccm.2016.04.006. Epub 2016 Jun 17. Review.

27.

Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.

Mucci A, Kunkiel J, Suzuki T, Brennig S, Glage S, Kühnel MP, Ackermann M, Happle C, Kuhn A, Schambach A, Trapnell BC, Hansen G, Moritz T, Lachmann N.

Stem Cell Reports. 2016 Aug 9;7(2):292-305. doi: 10.1016/j.stemcr.2016.06.011. Epub 2016 Jul 21.

28.

A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis.

Campo I, Luisetti M, Griese M, Trapnell BC, Bonella F, Grutters JC, Nakata K, Van Moorsel CH, Costabel U, Cottin V, Ichiwata T, Inoue Y, Braschi A, Bonizzoni G, Iotti GA, Tinelli C, Rodi G; WLL International Study Group.

Chest. 2016 Jul;150(1):251-3. doi: 10.1016/j.chest.2016.04.030. No abstract available.

29.

Respirable indium exposures, plasma indium, and respiratory health among indium-tin oxide (ITO) workers.

Cummings KJ, Virji MA, Park JY, Stanton ML, Edwards NT, Trapnell BC, Carey B, Stefaniak AB, Kreiss K.

Am J Ind Med. 2016 Jul;59(7):522-31. doi: 10.1002/ajim.22585. Epub 2016 May 24.

30.

Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle.

Schnepp BC, Chulay JD, Ye GJ, Flotte TR, Trapnell BC, Johnson PR.

Hum Gene Ther. 2016 Jan;27(1):32-42. doi: 10.1089/hum.2015.136.

31.

Diffuse Lung Disease in Biopsied Children 2 to 18 Years of Age. Application of the chILD Classification Scheme.

Fan LL, Dishop MK, Galambos C, Askin FB, White FV, Langston C, Liptzin DR, Kroehl ME, Deutsch GH, Young LR, Kurland G, Hagood J, Dell S, Trapnell BC, Deterding RR; Children’s Interstitial and Diffuse Lung Disease Research Network (chILDRN).

Ann Am Thorac Soc. 2015 Oct;12(10):1498-505. doi: 10.1513/AnnalsATS.201501-064OC.

32.
33.

A lymphocyte-mediated cause of secondary PAP.

Trapnell BC.

Blood. 2015 Jan 8;125(2):215-6. doi: 10.1182/blood-2014-11-610618.

34.

Early changes in clinical, functional, and laboratory biomarkers in workers at risk of indium lung disease.

Cummings KJ, Virji MA, Trapnell BC, Carey B, Healey T, Kreiss K.

Ann Am Thorac Soc. 2014 Nov;11(9):1395-403. doi: 10.1513/AnnalsATS.201407-346OC.

35.

Pulmonary macrophage transplantation therapy.

Suzuki T, Arumugam P, Sakagami T, Lachmann N, Chalk C, Sallese A, Abe S, Trapnell C, Carey B, Moritz T, Malik P, Lutzko C, Wood RE, Trapnell BC.

Nature. 2014 Oct 23;514(7523):450-4. doi: 10.1038/nature13807. Epub 2014 Oct 1.

36.

A standardized blood test for the routine clinical diagnosis of impaired GM-CSF signaling using flow cytometry.

Kusakabe Y, Uchida K, Hiruma T, Suzuki Y, Totsu T, Suzuki T, Carey BC, Yamada Y, Trapnell BC.

J Immunol Methods. 2014 Nov;413:1-11. doi: 10.1016/j.jim.2014.07.009. Epub 2014 Jul 26.

37.

The dawn of protein-folding therapeutics.

Trapnell BC.

Am J Respir Crit Care Med. 2014 Jan 1;189(1):1-3. doi: 10.1164/rccm.201310-1751ED. No abstract available.

PMID:
24381984
38.

Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis.

Suzuki T, Mayhew C, Sallese A, Chalk C, Carey BC, Malik P, Wood RE, Trapnell BC.

Am J Respir Crit Care Med. 2014 Jan 15;189(2):183-93. doi: 10.1164/rccm.201306-1039OC.

39.

Standardized serum GM-CSF autoantibody testing for the routine clinical diagnosis of autoimmune pulmonary alveolar proteinosis.

Uchida K, Nakata K, Carey B, Chalk C, Suzuki T, Sakagami T, Koch DE, Stevens C, Inoue Y, Yamada Y, Trapnell BC.

J Immunol Methods. 2014 Jan 15;402(1-2):57-70. doi: 10.1016/j.jim.2013.11.011. Epub 2013 Nov 23.

PMID:
24275678
40.

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression.

Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, McElvaney NG, Messina L, Tang Q, Rouhani FN, Campbell-Thompson M, Fu AD, Yachnis A, Knop DR, Ye GJ, Brantly M, Calcedo R, Somanathan S, Richman LP, Vonderheide RH, Hulme MA, Brusko TM, Wilson JM, Flotte TR.

J Clin Invest. 2013 Dec;123(12):5310-8. doi: 10.1172/JCI70314. Epub 2013 Nov 15.

41.

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.

Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group.

Lancet Respir Med. 2013 Aug;1(6):445-52.

42.

Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease.

Däbritz J, Bonkowski E, Chalk C, Trapnell BC, Langhorst J, Denson LA, Foell D.

Am J Gastroenterol. 2013 Dec;108(12):1901-10. doi: 10.1038/ajg.2013.360. Epub 2013 Oct 22.

PMID:
24145675
43.

The parallel lives of alpha1-antitrypsin deficiency and pulmonary alveolar proteinosis.

Trapnell BC, Luisetti M.

Orphanet J Rare Dis. 2013 Sep 30;8:153. doi: 10.1186/1750-1172-8-153. Review.

44.

Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies.

Dykes DM, Towbin AJ, Bonkowski E, Chalk C, Bezold R, Lake K, Kim MO, Heubi JE, Trapnell BC, Podberesky DJ, Denson LA.

Inflamm Bowel Dis. 2013 Sep;19(10):2146-54. doi: 10.1097/MIB.0b013e31829706e0.

45.

Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

Matthay MA, Anversa P, Bhattacharya J, Burnett BK, Chapman HA, Hare JM, Hei DJ, Hoffman AM, Kourembanas S, McKenna DH, Ortiz LA, Ott HC, Tente W, Thébaud B, Trapnell BC, Weiss DJ, Yuan JX, Blaisdell CJ.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS. Review.

46.

Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity.

Jurickova I, Collins MH, Chalk C, Seese A, Bezold R, Lake K, von Allmen D, Frischer JS, Falcone RA, Trapnell BC, Denson LA.

Clin Exp Immunol. 2013 Jun;172(3):455-65. doi: 10.1111/cei.12076.

47.

Assessment and management of pulmonary alveolar proteinosis in a reference center.

Campo I, Mariani F, Rodi G, Paracchini E, Tsana E, Piloni D, Nobili I, Kadija Z, Corsico A, Cerveri I, Chalk C, Trapnell BC, Braschi A, Tinelli C, Luisetti M.

Orphanet J Rare Dis. 2013 Mar 13;8:40. doi: 10.1186/1750-1172-8-40.

48.

Induced sputum biomarkers for monitoring cystic fibrosis lung disease.

Trapnell BC.

Am J Respir Crit Care Med. 2012 Nov 1;186(9):812-4. doi: 10.1164/rccm.201209-1731ED. No abstract available.

PMID:
23118078
49.

Inhaled dry powder mannitol: a solution for cystic fibrosis.

Trapnell BC.

Am J Respir Crit Care Med. 2012 Mar 15;185(6):596-8. doi: 10.1164/rccm.201112-2205ED. No abstract available.

PMID:
22422901
50.

Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.

Luisetti M, Balfour-Lynn IM, Johnson SR, Miravitlles M, Strange C, Trapnell BC, van Bronswijk H, Vogelmeier C.

Respir Med. 2012 Jun;106(6):759-68. doi: 10.1016/j.rmed.2012.02.016. Epub 2012 Mar 11. Review.

Supplemental Content

Loading ...
Support Center